P. Meza-junco J. Angulo

P. Meza-junco J. Angulo's AcademicInfluence.com Rankings

Philosophy

#6738

World Rank

#9829

Historical Rank

Logic

#3858

World Rank

#5078

Historical Rank

philosophy Degrees

Download Badge

Philosophy

P. Meza-junco J. Angulo's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is P. Meza-junco J. Angulo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

P. Meza-junco J. Angulo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (2005) (2733)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007) (2381)
Nonalcoholic fatty liver disease. (2002) (2147)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. (2015) (1958)
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis (1999) (1618)
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. (2003) (959)
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. (2005) (904)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (2004) (698)
Nonalcoholic fatty liver disease (2005) (652)
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years (2009) (647)
Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. (2015) (556)
Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis (2004) (474)
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study (2001) (417)
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. (2013) (417)
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study (2011) (403)
GI Epidemiology: nonalcoholic fatty liver disease (2007) (390)
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial (2008) (378)
NAFLD in children: A prospective clinical‐pathological study and effect of lifestyle advice (2006) (339)
Recent concepts in non‐alcoholic fatty liver disease (2005) (337)
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. (2005) (328)
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis (2015) (315)
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study (2008) (312)
The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis (2005) (301)
Obesity and nonalcoholic fatty liver disease. (2007) (268)
Noninvasive evaluation of NAFLD (2013) (262)
The natural history of small-duct primary sclerosing cholangitis. (2008) (255)
Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study (2010) (253)
A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis (2004) (246)
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction (2004) (225)
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease (2005) (216)
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis (2000) (211)
Long‐term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? (2010) (211)
Primary sclerosing cholangitis in children: A long‐term follow‐up study (2003) (210)
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis (2000) (209)
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial (2009) (206)
Chronological development of elevated aminotransferases in a nonalcoholic population (2005) (204)
Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study (2009) (199)
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. (2004) (197)
The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease (2004) (195)
Treatment of non-alcoholic fatty liver disease (2006) (195)
Small‐duct primary sclerosing cholangitis: A long‐term follow‐up study (2002) (191)
Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. (2000) (190)
Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. (1999) (179)
Is there a role for liver biopsy in primary sclerosing cholangitis? (2003) (166)
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. (2001) (161)
Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. (2011) (155)
Nutritional and Metabolic Considerations in the Etiology of Nonalcoholic Steatohepatitis (2001) (155)
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. (2000) (155)
The Framingham risk score and heart disease in nonalcoholic fatty liver disease (2012) (151)
Nonalcoholic fatty liver disease and liver transplantation (2006) (144)
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. (2010) (141)
Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo‐controlled trial (2005) (141)
Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes (2007) (136)
Serum autoantibodies in patients with primary sclerosing cholangitis. (2000) (134)
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis (1999) (133)
Treatment of nonalcoholic fatty liver: present and emerging therapies. (2001) (132)
Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. (1999) (127)
Tumor necrosis factor‐α and transforming growth factor‐β reflect severity of liver damage in primary biliary cirrhosis (2002) (125)
Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease (2007) (118)
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease (2007) (113)
Fat-soluble vitamin levels in patients with primary biliary cirrhosis (2000) (110)
NAFLD, obesity, and bariatric surgery. (2006) (105)
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? (2002) (104)
Utility of a new model to diagnose an alcohol basis for steatohepatitis. (2006) (103)
Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. (1998) (102)
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis (2004) (99)
Secondary Sclerosing Cholangitis: A Comparison to Primary Sclerosing Cholangitis (2005) (96)
Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (96)
Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications (2015) (95)
379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease (2014) (93)
Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. (2004) (90)
Cost‐minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis (2004) (90)
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. (1999) (86)
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. (2012) (85)
Bone disease in patients with primary sclerosing cholangitis. (2011) (83)
Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. (2002) (81)
Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. (2007) (81)
Oral budesonide in the treatment of primary sclerosing cholangitis (2000) (78)
Hepatitis C and steatosis. (2007) (78)
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? (2003) (76)
Treatment of nonalcoholic fatty liver disease. (2002) (76)
Primary sclerosing cholangitis (1999) (71)
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. (2012) (70)
Use of ursodeoxycholic acid in patients with liver disease (2002) (70)
The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease (2013) (70)
Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis (2006) (70)
Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience (2000) (69)
Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia (2007) (69)
Oral budesonide in the treatment of primary sclerosing cholangitis. (2000) (67)
Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. (2001) (66)
Nonalcoholic fatty liver disease (2005) (66)
Can NASH be diagnosed, graded, and staged noninvasively? (2012) (65)
Current best treatment for non-alcoholic fatty liver disease (2003) (61)
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. (2007) (58)
Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study (2005) (58)
Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease (2011) (58)
Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. (2005) (56)
An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. (2015) (56)
Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis (2007) (55)
Diagnosing steatohepatitis and predicting liver‐related mortality in patients with NAFLD: Two distinct concepts (2011) (52)
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus (2001) (51)
Erratum: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (Hepatology (2003) 37 (1202-1219)) (2003) (50)
Pirfenidone in the Treatment of Primary Sclerosing Cholangitis (2004) (50)
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system (2002) (50)
Oral Nicotine in Treatment of Primary Sclerosing Cholangitis (A Pilot Study) (2004) (49)
Safety and Efficacy of Estrogen Therapy in Preventing Bone Loss in Primary Biliary Cirrhosis (2003) (48)
Treatment of non-alcoholic steatohepatitis. (2002) (47)
Lactulose therapy in acute liver failure (2002) (46)
Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. (2014) (43)
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. (2012) (43)
The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease (2012) (39)
Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients With an Incomplete Response to Ursodeoxycholic Acid (2005) (39)
Non‐alcoholic fatty liver disease (2002) (39)
Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? (2001) (38)
Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study (2008) (38)
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy (2003) (37)
Time course of histological progression in primary sclerosing cholangitis (1999) (37)
Primary sclerosing cholangitis. (2008) (37)
Primary biliary cirrhosis and primary sclerosing cholangitis. (1999) (37)
Varices in Early Histological Stage Primary Biliary Cirrhosis (2011) (36)
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis (2002) (36)
Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small‐duct primary sclerosing cholangitis (2007) (35)
Time course of histological progression in primary sclerosing cholangitis. (1999) (35)
Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis (2003) (34)
A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis (2010) (34)
The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis (1998) (31)
Risk Factors for Venous Thromboembolism in Patients with Chronic Liver Disease (2013) (31)
Mycophenolate Mofetil for the Treatment of Primary Sclerosing Cholangitis (2005) (28)
The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis (2006) (28)
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. (2013) (27)
Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities? (2014) (27)
Association of Primary Biliary Cirrhosis and Rheumatoid Arthritis (2003) (22)
Open‐label pilot study of folic acid in patients with nonalcoholic steatohepatitis (2007) (21)
Noninvasive assessment of fibrosis and steatosis in NASH and ASH. (2009) (20)
Cholangiocarcinoma in pregnancy: A case report (2008) (17)
The Natural History of NAFLD (2013) (16)
Cetirizine-induced cholestasis (2000) (15)
Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid (2010) (12)
Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis (2001) (12)
Corrections: Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? (2010) (11)
Small-duct primary sclerosing cholangitis: Prevalence and natural history (2000) (10)
Management of primary biliary cirrhosis and autoimmune cholangitis. (1998) (10)
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers? (2004) (10)
Betaine for the treatment of nonalcoholic steatohepatitis: A promising new agent (2000) (9)
Medical treatment for primary sclerosing cholangitis: Risk versus benefit (2000) (9)
Primary sclerosing cholangitis. (2002) (8)
Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis. (2001) (8)
Primary sclerosing cholangitis: emerging new promising therapies. (2000) (8)
Nonalcoholic fatty liver disease in children: A follow-up study for up to 16 years (2003) (7)
Oral Tolerance and Pyruvate Dehydrogenase in Patients with Primary Biliary Cirrhosis (2002) (7)
Correction: Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial (2010) (6)
715 Hyaluronic acid, an accurate serum marker for advanced fibrosis among nonalcoholic steatohepatitis (2003) (6)
Right Upper-Quadrant Pain in a Patient with Drug Abuse, Secondary Syphilis and Occult Hepatitis B Virus (2014) (6)
Management of NASH: Current and Future Perspectives on Treatment (2007) (5)
S1908 Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study (2008) (5)
104 Time course of fibrosis progression in patients with nonalcoholic fatty liver disease (2003) (5)
The timing of liver transplantation in primary biliary cirrhosis. (2000) (5)
Clinical trials: Trial design in NASH—realities and challenges (2011) (4)
S1906 Lifestyle Intervention and Antioxidants in Children with Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial (2008) (4)
Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests (2015) (3)
Open-Label Pilot Study of Tetracycline in the Treatment of Primary Biliary Cirrhosis (2004) (3)
[Auto-antibodies in liver disease]. (2007) (3)
Mo1814 Fulminant Liver Failure Secondary to “Saba Appetite Control and Energy” Weight Loss Supplement (2014) (3)
Editorial: Noninvasive Prediction of Hepatic Steatosis (2014) (3)
Methotrexate in the treatment of primary biliary cirrhosis: the hype and the hope. (1999) (3)
Strengthening the bones in primary biliary cirrhosis (2013) (3)
714 Prevalence of autoantibodies and autoimmune hepatitis in nonalcoholic fatty liver disease (2003) (3)
Paroxysmal nocturnal hemoglobinuria presenting as acute renal failure. (1984) (2)
Mycophenolate mofetil for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2003) (2)
Oral nicotine in the treatment of primary sclerosing cholangitis: A pilot study (1998) (2)
LIVER FAILURE AND LIVER DISEASE LIVER FAILURE Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis : A Randomized Placebo-Controlled Trial (2005) (2)
[Acquired methemoglobinaemia (author's transl)]. (1981) (2)
Cetirizine-induce cholestasis. (2000) (2)
A Pilot Study: No Therapeutic Effect of L-Alanine in Patients with Nonalcoholic Steatohepatitis (2010) (2)
Insulin Resistance, Auto-antibodies, and Nonalcoholic Fatty Liver Disease Response to Letter (2005) (2)
Silymarin in the treatment of patients with primary scierosing cholangitis (2001) (2)
The bulge, booze, and the liver. (2005) (2)
The spectrum of nonalcoholic fatty liver disease with normal liver enzymes (2003) (2)
Hepatic Steatosis and Non‐Alcoholic Fatty Liver Disease (2010) (1)
731 Lipid profiles in nonalcoholic fatty liver disease (2003) (1)
Mycophenolate mofetil for patients with primary sclerosing cholangitis (2003) (1)
Long-term ursodeoxycholic acid therapy delays histologic progression in primary biliary cirrhosis (1998) (1)
814 Lactulose therapy in acute liver failure (2003) (1)
Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant? (2011) (1)
The time course of histological progression in primary sclerosing cholangitis (1998) (1)
Is there a role for liver biopsy in primary scierosing cholangitis (PSC) (2001) (1)
Relationship of serum cytokines and severity of liver damage in patients with nonalcoholic steatohepatitis (2001) (1)
Hormone replacement therapy is safe and effective in decreasing bone loss in postmenopausal patients with primary biliary cirrhosis (2000) (1)
Sarcopenic obesity and myosteratosis are associated with higher mortality in patients with cirrhosis (2016) (1)
Cryoglobulins in nonalcoholic Fatty-liver disease: what is the association? (2012) (1)
[Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months]. (1997) (1)
645 The Framingham Risk Score Accurately Predicts the Higher Risk of Coronary Heart Disease in Patients with Nonalcoholic Fatty Liver Disease (2009) (1)
Metabolic Syndrome and Non‐alcoholic Fatty Liver Disease (2016) (1)
Oral pirfenidone in the treatment of primary sclerosing cholangitis (2000) (1)
The Relationship of Steatosis Grade, Zone and Type to Key Histological Features in Children with Nonalcoholic Fatty Liver Disease: 1451 (2009) (0)
Evaluating Risks and Complications of Liver Biopsy in Children Receiving Biopsy for Diagnosis and Treatment: 435 (2013) (0)
Silymarin for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (0)
Serum cytokine levels in patients with primary sclerosing cholangitis: effect of treatment with ursodeoxycholic acid (2001) (0)
Sa1047 Increased Hepatic Iron Deposition and Long-Term Prognosis of Patients With Nonalcoholic Fatty Liver Disease (2014) (0)
Mo1001 Prognostic Relevance of Serum Ferritin in Patients With Nonalcoholic Fatty Liver Disease (2013) (0)
550 Immunomodulation of mediators of inflammation, fibrosis and apoptosis in primary biliary cirrhosis and primary sclerosing cholangitis (2004) (0)
Overlap with autoimmune hepatitis in pediatric patients with primary sclerosing cholangitis (2002) (0)
Acute Esophageal Necrosis: 95 (2013) (0)
Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply. (2012) (0)
[The effect of blood clotting on several fractions of the complement system (author's transl)]. (1976) (0)
Recurrent idiopathic hepatitis: a new entity? (2003) (0)
[Hemoblastosis and 2d hematic disease]. (1978) (0)
Adipose Tissue and Adipokines in Health and Disease. Humana Press, Totowa, New Jersey (2007), 402 pp. $169.00, ISBN 978-1-58829-721-1. Web site for ordering: www.humanapress.com (2008) (0)
Association of adiposity, measures of metabolic dysregulation, and elevated alanine aminotransferase in subjects with normal body mass index (2014) (0)
Independent predictors of severe liver fibrosis in chronic hepatitis C (2001) (0)
717 The spectrum of nonalcoholic fatty liver disease in patients with hypothalamic and pituitary dysfunction (2003) (0)
LIVER, PANCREAS, AND BILIARY TRACT Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease (2012) (0)
Weight gain precedes hypertransaminasemia and insulin resistance—A prospective study in healthy individuals (2003) (0)
Cytokines reflect the severity of the damage in non-alcoholic steatohepatitis (2002) (0)
747 Cytokine production and bone mineral density in patients with primary biliary cirrhosis (2003) (0)
Chapter 34. Nonalcoholic Fatty Liver Disease (2008) (0)
Overlap of autoimmune hepatitis with the newly modified scoring system (2000) (0)
[Hodgkin's disease. Our 9-year experience with the 1980 protocol]. (1992) (0)
465 Diabetes Increases the Risk of Hepatocellular Carcinoma in Non Alcoholic Steatohepatitis and Alcoholic Cirrhosis (2015) (0)
[The inulin test as a new screening method for the diagnosis of paroxysmal nocturnal hemoglobinuria]. (1973) (0)
Short-term ursodeoxycholic acid therapy delays stage progression in patients with primary biliary cirrhosis (2000) (0)
[Inulin induced platelet aggregation in patients with paroxysmal nocturnal haemoglobinuria (author's transl)]. (1976) (0)
Response to Dr. Sekhon (2002) (0)
Prevalence of celiac disease in a north american population with primary biliary cirrhosis - is screening worthwhile? (2000) (0)
Harnois et al.: Study of high-dose ursodeoxycholic acid [1] (multiple letters) (2002) (0)
[A new book interpretation of red blood cell heat-sensitivity in paroxysmal nocturnal haemoglobinuria (author's transl)]. (1976) (0)
[Cholestatic syndromes]. (2005) (0)
[Quantitative electroimmunodiffusion assessment of factor viii-associated antigen (author's transl)]. (1975) (0)
Nonalcoholic Fatty Liver Diseasea (2011) (0)
[Acceleration of coagulation by activation of the alternating route of complement]. (1974) (0)
Acknowledgment of 2008 Reviewers (2009) (0)
Relationship of serum cytokines and severity of liver damage in patients with nonalcoholic stestohepstitis (2001) (0)
Ursodeoxycholic acid therapy plays an immunomodulatory and anti-apoptotic role in patients with primary sclerosing cholangitis and primary biliary cirrhosis (2003) (0)
[Physiopathology of cellular abnormality in nocturnal paroxysmal hemoglobinuria]. (1978) (0)
Changes in Ca 19–9 over time predict development of cholangiocarcinoma in patients with primary sclerosing cholangitis (2003) (0)
372 Bone Disease in Patients With Primary Sclerosing Cholangitis: Prevalence, Predictors, and Rate of Progression (2010) (0)
[Fatty liver and steatotic non-alcoholic hepatitis]. (2004) (0)

This paper list is powered by the following services:

P. Meza-junco J. Angulo's Academic­Influence.com Rankings

P. Meza-junco J. Angulo's Degrees

Why Is P. Meza-junco J. Angulo Influential?

P. Meza-junco J. Angulo's Published Works

Published Works

P. Meza-junco J. Angulo's AcademicInfluence.com Rankings